Compare Trump Media and Technology Group Corp (DJT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs Incyte Corporation — how do they compare? Trump Media and Technology Group Corp trades at $8.28 (market cap $2.30B), while Incyte Corporation trades at $120.77 (market cap $24.48B). The key difference: Incyte Corporation is far larger — about 10.6× Trump Media and Technology Group Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| DJT | INCY | |
|---|---|---|
Market Cap | $2.30B | $24.48B |
Sector | Media | Health |
52-Week High | $18.50 | $129.93 |
52-Week Low | $7.06 | $81.66 |
Enterprise Value | $2.37B | $19.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT stock trades at $8.27, down 11.93% in the last session, reflecting bearish technical signals and fundamental challenges. The company reported Q2 2026 revenue of $1.67 million with a net loss of $238.1 million, driven by digital asset declines. Technical indicators show strong bearish momentum with support at $8 and resistance at $9-10 levels.
Outlook remains challenging with unsustainable valuation metrics (P/S ratio of 547.62) and persistent cash burn. Investment opportunities are limited given negative profitability and high business execution risks. Key risks include continued losses, competitive pressures, and volatile digital asset holdings affecting financial results.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
